Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALIVE: Albendazole-Ivermectin FDC for STH
NCT05124691Phase 3Terminated
- Sponsor
- Barcelona Institute for Global Health
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ivermectin in trichuriasis, hookworm infection, strongyloidiasis, sponsored by Barcelona Institute for Global Health. Started Jan 2022; status: terminated.
02
Drugs
ivermectin
03
Conditions
trichuriasishookworm infectionstrongyloidiasis
Beyond the preview
Go deeper on NCT05124691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124691.